The FY21 Defense Appropriations Act is anticipated to provide funding for the Department of Defense Melanoma Research Program to support innovative, high-impact melanoma research.
The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Kidney Cancer Research Program to support kidney cancer research. The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. The FY21 KCRP program announcements... […]
The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation have announced funding opportunities in lung cancer research for FY21.
Stand Up To Cancer has announced $3.25 million in grants from four nonprofits to fund research to find new treatments for head and neck cancers.
Although FY21 funds have not been appropriated for the Department of Defense Ovarian Cancer Research Program, the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities.
Israel Cancer Research Fund has announced 69 cancer research grants, valued at $4.7 million, will be supported for the 2020-2021 funding year.
The Lymphoma Research Foundation has announced the establishment of the Jaime Peykoff Follicular Lymphoma Initiative, named for follicular lymphoma survivor and wife of Andrew Peykoff II, owner of Niagara Bottling.
The Mark Foundation for Cancer Research is announcing the launch of a funding program that supports the development of novel cancer therapeutics in areas with high unmet needs. These Drug Discovery Partnership awards are structured to support high-risk, high-reward research and bridge the substantial gap in advancing promising academic discoveries to novel therapies.
